Business Description
![Antibe Therapeutics Inc Antibe Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000A59W.png?14)
Antibe Therapeutics Inc
NAICS : 541714
SIC : 3741
ISIN : CA0370251039
Compare
Compare
Traded in other countries / regions
ATE.Canada4B70.GermanyATBPF.USA IPO Date
2013-06-18Description
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.46 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17.6 | |||||
3-Year EPS without NRI Growth Rate | 17.9 | |||||
3-Year FCF Growth Rate | 9.1 | |||||
3-Year Book Growth Rate | 80.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.62 | |||||
9-Day RSI | 39.4 | |||||
14-Day RSI | 35.69 | |||||
6-1 Month Momentum % | -59.59 | |||||
12-1 Month Momentum % | -39.8 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.06 | |||||
Quick Ratio | 10.06 | |||||
Cash Ratio | 8.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.5 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -53.35 | |||||
ROA % | -28.31 | |||||
ROIC % | -68.45 | |||||
ROC (Joel Greenblatt) % | -1933.62 | |||||
ROCE % | -29.22 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.6 | |||||
EV-to-EBIT | 2.15 | |||||
EV-to-EBITDA | 2.15 | |||||
EV-to-FCF | 2.15 | |||||
Earnings Yield (Greenblatt) % | 46.51 | |||||
FCF Yield % | -116.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Antibe Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | |||
EPS (TTM) (C$) | -0.35 | ||
Beta | 0 | ||
Volatility % | 86.55 | ||
14-Day RSI | 35.69 | ||
14-Day ATR (C$) | 0.005876 | ||
20-Day SMA (C$) | 0.295 | ||
12-1 Month Momentum % | -39.8 | ||
52-Week Range (C$) | 0.15 - 1.23 | ||
Shares Outstanding (Mil) | 53.01 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Antibe Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Antibe Therapeutics Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Antibe Therapeutics Inc Frequently Asked Questions
What is Antibe Therapeutics Inc(TSX:ATE)'s stock price today?
The current price of TSX:ATE is C$0.30. The 52 week high of TSX:ATE is C$1.23 and 52 week low is C$0.15.
When is next earnings date of Antibe Therapeutics Inc(TSX:ATE)?
The next earnings date of Antibe Therapeutics Inc(TSX:ATE) is .
Does Antibe Therapeutics Inc(TSX:ATE) pay dividends? If so, how much?
Antibe Therapeutics Inc(TSX:ATE) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |